title: Targeting notch pathway enhances rapamycin antitumor activity in pancreas cancers through PTEN phosphorylation.
abstract: BACKGROUND
  Pancreas cancer is one of most aggressive human cancers with the survival rate for patients with metastatic pancreas cancer at 5-6 months. The poor survival demonstrates a clear need for better target identification, drug development and new therapeutic strategies. Recent discoveries have shown that the role for Notch pathway is important in both development and cancer. Its contribution to oncogenesis also involves crosstalks with other growth factor pathways, such as Akt and its modulator, PTEN. The mounting evidence supporting a role for Notch in cancer promotion and survival suggests that targeting this pathway alone or in combination with other therapeutics represents a promising therapeutic strategy.
  
  
  RESULTS
  Using a pancreas cancer tissue microarray, we noted that Jagged1, Notch3 and Notch4 are overexpressed in pancreas tumors (26%, 84% and 31% respectively), whereas Notch1 is expressed in blood vessels. While there was no correlation between Notch receptor expression and survival, stage or tumor grade, Notch3 was associated with Jagged1 and EGFR expression, suggesting a unique relationship between Notch3 and Jagged1. Inhibition of the Notch pathway genetically and with gamma-secretase inhibitor (GSI) resulted in tumor suppression and enhanced cell death. The observed anti-tumor activity appeared to be through Akt and modulation of PTEN phosphorylation. We discovered that transcriptional regulation of RhoA by Notch is important for PTEN phosphorylation. Finally, the mTOR inhibitor Rapamycin enhanced the effect of GSI on RhoA expression, resulting in down regulation of phospho-Akt and increased in vitro tumor cytotoxity.
  
  
  CONCLUSIONS
  Notch pathway plays an important role in maintaining pancreas tumor phenotype. Targeting this pathway represents a reasonable strategy for the treatment of pancreas cancers. Notch modulates the Akt pathway through regulation of PTEN phosphorylation, an observation that has not been made previously. Furthermore, we discovered that this regulation is dependent on RhoA/Rock1 activation. Enhanced phospho-Akt suppression when GSI is combined with rapamycin suggests that targeting both pathways will lead to a greater efficacy in the treatment of patients with pancreas cancer.
authors.affiliation: College of Pharmacy, The University of Tennessee, Memphis, TN, USA.
authors.forename: Kevin
authors.initials: K
authors.lastname: Vo
authors.forename: Barushi
authors.initials: B
authors.lastname: Amarasinghe
authors.forename: Kay
authors.initials: K
authors.lastname: Washington
authors.forename: Adriana
authors.initials: A
authors.lastname: Gonzalez
authors.forename: Jordan
authors.initials: J
authors.lastname: Berlin
authors.forename: Thao P
authors.initials: TP
authors.lastname: Dang
mesh_terms: D053829:Amyloid Precursor Protein Secretases / Q000037:antagonists & inhibitors / Q000378:metabolism; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology* / Q000627:therapeutic use; D045744:Cell Line, Tumor; D005260:Female; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D051059:PTEN Phosphohydrolase / Q000235:genetics / Q000378:metabolism*; D010190:Pancreatic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D010766:Phosphorylation; D051880:Receptors, Notch / Q000037:antagonists & inhibitors* / Q000235:genetics / Q000378:metabolism; D015398:Signal Transduction / Q000235:genetics*; D020123:Sirolimus / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000903:Antibiotics, Antineoplastic; D051880:Receptors, Notch; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human; D053829:Amyloid Precursor Protein Secretases; D020123:Sirolimus
references.citation: Nat Rev Drug Discov. 2009 Aug;8(8):627-44
references.pmid: 19644473
references.citation: Cancer Cell. 2003 Jun;3(6):565-76
references.pmid: 12842085
references.citation: Gene. 2006 Jun 7;374:1-9
references.pmid: 16675164
references.citation: EMBO J. 2004 Mar 10;23(5):1155-65
references.pmid: 14976548
references.citation: Cancer Res. 2005 May 1;65(9):3555-61
references.pmid: 15867348
references.citation: J Biol Chem. 2004 Jan 23;279(4):2937-44
references.pmid: 14583609
references.citation: J Clin Invest. 2000 Mar;105(5):597-605
references.pmid: 10712431
references.citation: Genes Dev. 2006 Nov 15;20(22):3147-60
references.pmid: 17114585
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5513-8
references.pmid: 19858379
references.citation: J Clin Oncol. 2009 Jan 10;27(2):193-8
references.pmid: 19047305
references.citation: Cancer Res. 2006 Feb 1;66(3):1500-8
references.pmid: 16452206
references.citation: Cancer Res. 2008 Jul 15;68(14):5716-23
references.pmid: 18632624
references.citation: Blood. 2006 Feb 1;107(3):931-9
references.pmid: 16219802
references.citation: Oncogene. 2010 Jan 28;29(4):589-96
references.pmid: 19881544
references.citation: Curr Biol. 2000 Apr 6;10(7):401-4
references.pmid: 10753747
references.citation: Proc Natl Acad Sci U S A. 2010 Jul 27;107(30):13438-43
references.pmid: 20624967
references.citation: Chem Biol. 2007 Feb;14(2):209-19
references.pmid: 17317574
references.citation: Oncogene. 2010 Apr 29;29(17):2488-98
references.pmid: 20154720
references.citation: Cell. 2009 Apr 17;137(2):216-33
references.pmid: 19379690
references.citation: Nat Rev Cancer. 2002 Feb;2(2):133-42
references.pmid: 12635176
references.citation: Cancer Cell. 2007 Nov;12(5):411-3
references.pmid: 17996644
references.citation: PLoS One. 2010 Oct 22;5(10):e13572
references.pmid: 21042581
references.citation: FEBS Lett. 2011 Jan 21;585(2):286-90
references.pmid: 21167153
references.citation: CA Cancer J Clin. 2010 Sep-Oct;60(5):277-300
references.pmid: 20610543
references.citation: Nat Cell Biol. 2005 Apr;7(4):399-404
references.pmid: 15793569
references.citation: J Biol Chem. 2001 Dec 28;276(52):48627-30
references.pmid: 11707428
references.citation: Blood. 2010 Mar 4;115(9):1785-96
references.pmid: 20008297
references.citation: Nat Genet. 2000 Jan;24(1):36-44
references.pmid: 10615124
references.citation: Mol Cell Biol. 2000 Jul;20(14):5010-8
references.pmid: 10866658